Jefferies Financial Group Inc. Purchases New Position in Replimune Group, Inc. $REPL

Jefferies Financial Group Inc. purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 714,226 shares of the company’s stock, valued at approximately $6,942,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Fcpm Iii Services B.V. raised its holdings in shares of Replimune Group by 6.4% in the third quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after buying an additional 248,672 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Replimune Group by 0.3% in the third quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock valued at $14,579,000 after buying an additional 9,707 shares during the last quarter. Braidwell LP raised its holdings in shares of Replimune Group by 550.3% in the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after buying an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. raised its holdings in shares of Replimune Group by 507.4% in the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock valued at $11,012,000 after buying an additional 2,195,448 shares during the last quarter. Finally, Readystate Asset Management LP raised its holdings in shares of Replimune Group by 1,296.2% in the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after buying an additional 2,433,292 shares during the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Price Performance

REPL stock opened at $4.91 on Tuesday. The company’s 50 day simple moving average is $4.99 and its 200-day simple moving average is $7.33. The firm has a market capitalization of $405.42 million, a PE ratio of -1.43 and a beta of 0.12. Replimune Group, Inc. has a 12 month low of $1.50 and a 12 month high of $13.24. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on REPL. Weiss Ratings raised shares of Replimune Group from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 8th. Piper Sandler cut shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a report on Friday, April 10th. Cantor Fitzgerald cut shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Wedbush reaffirmed a “neutral” rating and issued a $2.00 target price (down from $19.00) on shares of Replimune Group in a report on Monday, April 13th. Finally, Wall Street Zen raised shares of Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday. Six research analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $4.75.

Insider Activity

In related news, insider Christopher Sarchi sold 6,500 shares of the company’s stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total transaction of $52,065.00. Following the transaction, the insider owned 151,588 shares of the company’s stock, valued at approximately $1,214,219.88. This represents a 4.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.